TY - JOUR

T1 - Kosteneffektivität von pharmakologischen Raucherentwöhnungsmaßnahmen

T2 - ein systematisches Literaturreview

AU - Aumann, I.

AU - Rozanski, K.

AU - Damm, K.

AU - Graf Von Der Schulenburg, J. M.

PY - 2016/10

Y1 - 2016/10

N2 - Aim of the Study: Through the promotion of smoking cessation premature mortality can be prevented. Therefore it is necessary to provide effective and cost-effective smoking cessation interventions. In Germany the cost of pharmacological smoking cessation measures are not yet reimbursed by the statutory health insurance. The aim of this study is to present the evidence on the cost-effectiveness of already approved pharmacological smoking cessation therapies and to evaluate their quality. Method: A systematic literature research was conducted in the databases by DIMDI (Medline, Embase, etc.) in April 2013 (update April 2014). The study research was focused on studies for cost effectiveness of nicotine replacement therapy (NRT), varenicline and bupropion. The assessment of study quality was performed using the quo;Quality of Health Economic Studies (QHES) instrument. Results: 33 Of the original 10 340 identified studies were finally included. The majority of the studies show that an additional prescription of NRT or bupropion to a medical consultation is a cost-effective strategy. In addition, in most studies varenicline is a dominant strategy compared to bupropion. Overall, the study quality was found to be very heterogeneous between 45 and 80 points (O 63.7 points). Conclusion: The studies show that treatment with varenicline is the most cost effective strategy followed by bupropion and the NRT. However, the studies can only be compared inadequately due to different levels of age and country-specific intervention costs.

AB - Aim of the Study: Through the promotion of smoking cessation premature mortality can be prevented. Therefore it is necessary to provide effective and cost-effective smoking cessation interventions. In Germany the cost of pharmacological smoking cessation measures are not yet reimbursed by the statutory health insurance. The aim of this study is to present the evidence on the cost-effectiveness of already approved pharmacological smoking cessation therapies and to evaluate their quality. Method: A systematic literature research was conducted in the databases by DIMDI (Medline, Embase, etc.) in April 2013 (update April 2014). The study research was focused on studies for cost effectiveness of nicotine replacement therapy (NRT), varenicline and bupropion. The assessment of study quality was performed using the quo;Quality of Health Economic Studies (QHES) instrument. Results: 33 Of the original 10 340 identified studies were finally included. The majority of the studies show that an additional prescription of NRT or bupropion to a medical consultation is a cost-effective strategy. In addition, in most studies varenicline is a dominant strategy compared to bupropion. Overall, the study quality was found to be very heterogeneous between 45 and 80 points (O 63.7 points). Conclusion: The studies show that treatment with varenicline is the most cost effective strategy followed by bupropion and the NRT. However, the studies can only be compared inadequately due to different levels of age and country-specific intervention costs.

KW - bupropion

KW - cost-effectiveness

KW - nicotine

KW - pharmacological smoking cessation therapies

KW - vareniclin

UR - http://www.scopus.com/inward/record.url?scp=84994031541&partnerID=8YFLogxK

U2 - 10.1055/s-0035-1548852

DO - 10.1055/s-0035-1548852

M3 - Artikel

C2 - 27784123

AN - SCOPUS:84994031541

VL - 78

SP - 660

EP - 671

JO - GESUNDHEITSWESEN

JF - GESUNDHEITSWESEN

SN - 0941-3790

IS - 10

ER -